Get started
Author

Asrar A. Alahmadi

Observed names: A. AlAhmadi, A. Alahmadi, Asrar Al Ahmadi, Asrar Al-Ahmadi, Asrar AlAhmadi, Asrar Alahmadi
Observed institutions: University Hospitals of Cleveland, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Wexner Medical Center, University Hospitals Cleveland Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, The Ohio State University, Case Western Reserve University
ORCID: 0000-0001-7385-2843
Observed ORCID: 0000-0001-7385-2843
OpenAlex ID: A5020594501
Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer
2021 · Caroline A. Nebhan, Alessio Cortellini, et al. · JAMA Oncology · 160
Association Between Pretreatment Chest Imaging and Immune Checkpoint Inhibitor Pneumonitis Among Patients With Lung Cancer
2023 · Alexander Wong, Maria Riley, et al. · Journal of the National Comprehensive Cancer Network · 26
PDF
Retinoblastoma Expression and Targeting by CDK4/6 Inhibitors in Small Cell Lung Cancer
2022 · Gary Wildey, Ashley M. Shay, et al. · Molecular Cancer Therapeutics · 25
PDF
Next Generation Sequencing of Advanced Non–Small Cell Lung Cancer: Utilization Based on Race and Impact on Survival
2020 · Asrar Al-Ahmadi, Fatemeh Ardeshir-Larijani, et al. · Clinical Lung Cancer · 24
Mean platelet volume, thrombocytosis, and survival in non-small cell lung cancer patients treated with first-line pembrolizumab alone or with chemotherapy
2023 · Mingjia Li, Songzhu Zhao, et al. · Cancer Immunology Immunotherapy · 13
PDF
Myocarditis associated with immune checkpoint inhibitor therapy: a case report of three patients
2020 · Kianoush Ansari-Gilani, Sree Harsha Tirumani, et al. · Emergency Radiology · 13
Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort study
2024 · Kylie Fletcher, Alessio Cortellini, et al. · Cancer Letters · 9
Older Patients with Lung Cancer: a Summary of Seminal Contributions to Optimal Patient Care
2022 · Alina Basnet, Asrar Alahmadi, et al. · Current Oncology Reports · 9
Evaluating the effect of immune checkpoint inhibitor treatment on chronic obstructive pulmonary disease in lung cancer patients
2025 · Anet Greib, Songzhu Zhao, et al. · OncoImmunology · 8
State of Lung Cancer in Egypt: Moving Towards Improved Guidelines for Prevention, Screening, Treatment, and Clinical Care Programs
2024 · Nagla Abdel Karim, Ahmed Magdy Rabea, et al. · JTO Clinical and Research Reports · 8
PDF
Associations of Racial and Ethnic Category, Age, Comorbidities, and Socioeconomic Factors on Concordance to NCCN Guidelines for Patients With High-Risk Biliary Tract Cancers After Surgery
2022 · Lauren F. Huang, Augustine Hong, et al. · Frontiers in Oncology · 8
PDF
Adoption of single agent anticancer therapy for advanced hepatocellular carcinoma and impact of facility type, insurance status, and income on survival: Analysis of the national cancer database 2004–2014
2021 · Aman Opneja, Gino Cioffi, et al. · Cancer Medicine · 6
PDF
Outcomes of Antineoplastic Immunotherapy at a Large Healthcare Organization: Impact of Provider, Race and Socioeconomic Status
2023 · Matthew M Mirsky, Carley Mitchell, et al. · Cancer Management and Research · 5
PDF
Mistletoe Extract Viscum Fraxini-2 for Treatment of Advanced Hepatocellular Carcinoma: A Case Series
2021 · Richard T. Lee, Peiying Yang, et al. · Case Reports in Oncology · 4
Safety and efficacy of single-agent adjuvant trastuzumab in older women with early-stage breast cancer.
2020 · Cynthia Owusu, Seunghee P Margevicius, et al. · Journal of Clinical Oncology · 4
Early Changes in Lymphocyte/Monocyte Ratio on Treatment as a Prognostic Marker to Predict Overall Survival in Patients with Advanced Cancer Treated with Immune Checkpoint Inhibitors
2025 · Sandip H. Patel, Songzhu Zhao, et al. · Cancer Investigation · 3
PDF
Utility of multidisciplinary tumor board (MTB) in the management of hepatocellular cancer (HCC)
2016 · A. Alahmadi, R. Lee, et al. · Annals of Oncology · 3
CLO25-080: Outcomes of Extreme Low PD-L1 Expression in Advanced Non-Small Cell Lung Cancer: Implications for Treatment Approaches
2025 · Alexander Rudich, Natalie Johns, et al. · Journal of the National Comprehensive Cancer Network · 1
Trends in Mesothelioma Mortality in the United States Between 1999 and 2020
2025 · Alexander J. Didier, Mingjia Li, et al. · JTO Clinical and Research Reports · 1
PDF
Eosinophil-neutrophil ratio as a sex-dependent prognostic marker in immune checkpoint therapy for metastatic NSCLC and transcriptomic evaluation of intratumoral eosinophil-T cell interaction.
2024 · Hyunwoo Kwon, Mingjia Li, et al. · Journal of Clinical Oncology · 1
Real world outcomes of patients treated with first line chemo-immunotherapy (IO) for small cell lung cancer (SCLC): Impact of brain metastases and patterns of subsequent therapy.
2023 · Saira Farid, Songzhu Zhao, et al. · Journal of Clinical Oncology · 1
Primary liver angiosarcoma and factors associated with improved outcomes: An analysis of the National Cancer Database.
2020 · Prantesh Jain, Gino Cioffi, et al. · Journal of Clinical Oncology · 1
Impact of facility type, insurance status, and income on use of single agent chemotherapy (SACT) for advanced hepatocellular carcinoma (AHCC): Analysis of National Cancer Database (NCDB).
2020 · Richard T. Lee, Gino Cioffi, et al. · Journal of Clinical Oncology · 1
The impact of sorafenib on the treatment and survival of advanced hepatocellular carcinoma (HCC): Analysis of the National Cancer Database (NCDB) from 2004 to 2014.
2019 · Aman Opneja, Gino Cioffi, et al. · Journal of Clinical Oncology · 1
Subtype-Agnostic Biomarkers of Immunotherapy Response in Lung Cancer
2026 · Elisa Gobbini, Subhamoy Chakraborty, et al. · Cancer Immunology Research
Works count: 68
Citation count: 335
H-index: 8
I10-index: 6
Year
Topic
Type